KP Tissue Inc. (OTC:KPTSF) Surpasses EPS Estimates but Misses on Revenue

• KP Tissue Inc. (OTC:KPTSF) reported an EPS of $0.43, exceeding expectations.
• The company's revenue of $407.8 million fell short of the forecasted $553.2 million.
• KPTSF maintains a current ratio of 1, indicating financial stability.

KP Tissue Inc. (OTC:KPTSF) is a key player in the competitive tissue product market, alongside giants like Kimberly-Clark and Procter & Gamble. On February 18, 2026, the company announced its earnings, revealing an EPS of $0.43, which significantly surpassed the estimated $0.18. Despite this achievement, KP Tissue's revenue of $407.8 million did not meet the anticipated $553.2 million.

During the Q4 2025 earnings call, KP Tissue Inc. provided valuable insights into its financial health and operational strategies. Although the revenue did not reach expectations, the company showcased a P/E ratio of 27.49, reflecting strong investor confidence in its future earnings potential. Additionally, an earnings yield of 3.64% was reported, indicating a favorable return on investment for shareholders.

The company's current ratio of 1 demonstrates its capability to cover short-term liabilities with its short-term assets, highlighting its financial stability. The earnings call also likely touched upon market conditions and strategic initiatives aimed at enhancing revenue and profitability.